Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has issued an announcement.
Pharmaron Beijing Co., Ltd. has announced its first extraordinary general meeting of 2025, scheduled for December 18, 2025. The meeting will address several resolutions including the by-election of an independent non-executive director and amendments to various management policies and articles of association. These changes are aimed at enhancing corporate governance and operational efficiency, potentially impacting the company’s strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on providing R&D services to the life sciences industry, offering a range of services including drug discovery, development, and manufacturing.
Average Trading Volume: 9,044,582
Technical Sentiment Signal: Buy
Current Market Cap: HK$53.14B
Learn more about 3759 stock on TipRanks’ Stock Analysis page.